Department of Orthopedics and Sports Medicine, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, PR China.
Department of Traumatology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou Industry Park, Suzhou, PR China.
Trials. 2022 Dec 5;23(1):977. doi: 10.1186/s13063-022-06886-6.
Arthroscopic rotator cuff repair (ARCR) often causes unbearable postoperative pain, even more severe than before surgery. Opioids are the drugs of choice for temporary postoperative analgesia. However, this conventional approach also has some side effects and potential for drug abuse. The aims of this study are expected to verify the effect of 5% lidocaine patch (LP5) on the intensity of early postoperative pain, functional recovery and quality of life in patients undergoing ARCR.
In this randomized, double-blind, and placebo-controlled clinical trial, a total of 102 postoperative patients undergoing ARCR will be randomly assigned to either the LP5 group, receiving topical lidocaine analgesia, or the placebo control group. The primary outcome measure will be the change in the American Shoulder Elbow Surgeons score from pre-operation to 90 days post-operation. Secondary outcomes will include pain scores, range of motion, opioid use, safety indicators, blinding assessment and several shoulder function score questionnaires. The effect of the allocated treatment will be assessed at preoperative baseline and at 7-, 14-, 30- and 90-day postoperatively.
In this study, the efficacy and safety of the 5% lidocaine patch will be evaluated in terms of short-term clinical symptoms in patients undergoing ARCR. The results of this study will help determine whether LP5 is effective in early functional recovery in ARCR and whether it relieves pain and reduces opioid consumption.
Chinese Clinical Trial Registry ( http://www.chictr.org.cn ) ChiCTR2200060108. Registered on 19 May 2022.
关节镜下肩袖修复术(ARCR)常引起难以忍受的术后疼痛,甚至比术前更严重。阿片类药物是临时术后镇痛的首选药物。然而,这种传统方法也有一些副作用和滥用药物的潜在风险。本研究旨在验证 5%利多卡因贴剂(LP5)对接受 ARCR 的患者早期术后疼痛强度、功能恢复和生活质量的影响。
在这项随机、双盲、安慰剂对照的临床试验中,共有 102 名接受 ARCR 的术后患者将被随机分配到 LP5 组(接受局部利多卡因镇痛)或安慰剂对照组。主要观察指标为美国肩肘外科医生评分从术前到术后 90 天的变化。次要观察指标包括疼痛评分、活动范围、阿片类药物使用、安全性指标、盲法评估和几项肩部功能评分问卷。将在术前基线和术后 7、14、30 和 90 天评估分配治疗的效果。
在这项研究中,将评估 5%利多卡因贴剂在接受 ARCR 的患者短期临床症状方面的疗效和安全性。这项研究的结果将有助于确定 LP5 是否能有效促进 ARCR 的早期功能恢复,是否能缓解疼痛和减少阿片类药物的使用。
中国临床试验注册中心(http://www.chictr.org.cn),ChiCTR2200060108,于 2022 年 5 月 19 日注册。